ID Biomedical announces 2005 first quarter release date and conference call
May 11 2005 - 10:30AM
PR Newswire (US)
ID Biomedical announces 2005 first quarter release date and
conference call VANCOUVER, May 11 /PRNewswire-FirstCall/ -- ID
Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today
that it will report its 2005 first quarter results on Monday, May
16, 2005 at 4:00 pm Eastern. The Company will follow the results
with a conference call/web cast at 5:00 pm Eastern / 2:00 pm
Pacific. The call can be accessed by dialing (604) 677-8677 or by
logging onto the Company's website at http://www.idbiomedical.com/.
A replay of the call is available until May 30 by dialing (416)
640-1917. The pass code is 21123931 followed by the numbered sign.
About ID Biomedical ID Biomedical is an integrated biotechnology
company dedicated to the development of innovative vaccine
products. It operates in research, development, manufacturing,
sales and marketing from its facilities in Canada and in the United
States. ID Biomedical is dedicated to becoming a premier vaccine
company with significant marketed products worldwide and an
extensive pipeline in both clinical and preclinical development. ID
Biomedical has a leading position in the Canadian influenza vaccine
market. It received a ten-year mandate from the Government of
Canada in 2001 to assure a state of readiness in the case of an
influenza pandemic and provide influenza vaccine for all Canadians
in such an event. It also currently supplies approximately 75% of
the Canadian government's influenza vaccine purchases. For further
information on ID Biomedical, please visit the Company's website at
http://www.idbiomedical.com/. The information in this news release
contains so-called "forward-looking" statements. These include
statements regarding ID Biomedical's expectations and plans
relating to the integration of the vaccine business acquired from
Shire, statements about ID Biomedical's expectations, beliefs,
intentions or strategies for the future, which may be indicated by
words or phrases such as "anticipate", "expect", "intend", "plan",
"will", "we believe", "ID Biomedical believes", "management
believes", and similar language. All forward-looking statements are
based on ID Biomedical's current expectations and are subject to
risks and uncertainties and to assumptions made. Important factors
that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements include:
(i) the company's ability to successfully integrate the Shire
vaccine business; (ii) the company's ability to successfully
complete preclinical and clinical development of its products;
(iii) the company's ability to manufacture its products; (iv) the
seasonality of the flu-vaccine business and related fluctuations in
the company's revenues from quarter to quarter; (v) decisions, and
the timing of decisions, made by the health regulatory agencies
regarding approval of its products for human testing; (vi) the
company's ability to enter into distribution agreements for its
products, and to complete and maintain corporate alliances relating
to the development and commercialization of its technology and
products; (vii) market acceptance of its technologies and products;
and (viii) the competitive environment and impact of technological
change and other risks detailed in the company's filings with the
Securities and Exchange Commission. ID Biomedical bases its
forward-looking statements on information currently available to
it, and assumes no obligation to update them. For further
information, please contact: Investor Relations/Media Dean Linden
(604) 431-9314 Michele Roy (450) 978-6313 DATASOURCE: ID Biomedical
Corporation CONTACT: Investor Relations/Media, Dean Linden, (604)
431-9314, ; Michele Roy, (450) 978-6313, ; To request a free copy
of this organization's annual report, please go to
http://www.newswire.ca/ and click on reports@cnw.
Copyright